Toboroz
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
2025-524283-38-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Még nem toboroz
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Még nem toboroz
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· 3. fázis· The Netherlands Cancer Institute· Forrás
Toboroz
A study to investigate the efficacy, safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
2025-520518-79-00· 2. fázis· Novartis Pharma AG· Forrás
Toboroz
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
NCT07188025· 3. fázis· Erasmus Medical Center· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).
2024-518171-59-00· 4. fázis· Canisius Wilhelmina Ziekenhuis· Forrás
Toboroz
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
NCT06766461· 4. fázis· Erasmus Medical Center· Forrás
Fut, nem toboroz
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· 3. fázis· Amgen· Forrás
Toboroz
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· 4. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
Ulipristal versus surgery for symptomatic uterine fibroids
2024-512602-26-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
NCT06220032· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
NCT04225312· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06275958· 3. fázis· Leiden University Medical Center· Forrás
Toboroz
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
EASYlight study
2023-508417-16-00· 4. fázis· Reinier de Graaf Groep· Forrás
Toboroz
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· 4. fázis· Amsterdam UMC· Forrás
Fut, nem toboroz
MAD Trial: Myopia Atropine Dose
NCT05667454· 3. fázis· Erasmus Medical Center· Forrás
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616· 3. fázis· University College, London· Forrás
Fut, nem toboroz
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Fut, nem toboroz
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159· 3. fázis· Population Health Research Institute· Forrás
Toboroz
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
NCT04523428· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
NCT04097470· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
G7 BiSpherical Acetabular Shell PMCF Study
NCT03266874· Zimmer Biomet· Forrás
Toboroz
DRUP trial
NCT02925234· 2. fázis· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Forrás
Fut, nem toboroz
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117· 2. fázis· The Netherlands Cancer Institute· Forrás
Fut, nem toboroz
PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
NCT03372278· Zimmer Biomet· Forrás
Fut, nem toboroz
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
NCT01558921· 3. fázis· University Medical Center Groningen· Forrás
Fut, nem toboroz
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01057069· 2/3. fázis· The Netherlands Cancer Institute· Forrás